ArticleJournal of controlled release : official journal of the Controlled Release Society2012
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Unlocking the Potential of Spheroids in Personalized Medicine: A Systematic Review of Seeding Methodologies.International journal of molecular sciences · 2025Pooled it
- Review
- Multi-functional near-infrared fluorescent polymer dot-siRNA for gene expression regulation.Journal of materials chemistry. B · 2025Article
- A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine.Current cancer drug targets · 2025Review
- Revolutionizing Retinal Therapy: The Role of Nanoparticle Drug Carriers in Managing Vascular Retinal Disorders.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- The interplay of cells, polymers, and vascularization in three-dimensional lung models and their applications in COVID-19 research and therapy.Stem cell research & therapy · 2023Review
- Tumor Organoid and Spheroid Models for Cervical Cancer.Cancers · 2023Review
- Article
- Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery.Journal of nanobiotechnology · 2022Review
- Particle Engineering of Innovative Nanoemulsion Designs to Modify the Accumulation in Female Sex Organs by Particle Size and Surface Charge.Pharmaceutics · 2022Article
- The Effects of Curcumin Nanoparticles Incorporated into Collagen-Alginate Scaffold on Wound Healing of Skin Tissue in Trauma Patients.Polymers · 2021Article
- 3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.International journal of molecular sciences · 2021Review
- Recent Advances in Three-Dimensional Multicellular Spheroid Culture and Future Development.Micromachines · 2021Review
- Cytotoxicity Effects of Curcumin Loaded on Chitosan Alginate Nanospheres on the KMBC-10 Spheroids Cell Line.International journal of nanomedicine · 2021Article
- Long-term monitoring in a microfluidic system to study tumour spheroid response to chronic and cycling hypoxia.Scientific reports · 2019Article
- Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for Targeting of B-cell Lymphoma.ACS omega · 2019Article
- Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment.Scientific reports · 2019Article
- Tailoring the lipid composition of nanoparticles modulates their cellular uptake and affects the viability of triple negative breast cancer cells.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Liver-Targeted Combination Therapy Basing on Glycyrrhizic Acid-Modified DSPE-PEG-PEI Nanoparticles for Co-delivery of Doxorubicin and Bcl-2 siRNA.Frontiers in pharmacology · 2019Article
- Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency.International journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We describe the evaluation of doxorubicin-loaded PEG-PE micelles targeting using an ovarian cancer cell spheroid model. Most ovarian cancer patients present at an advanced clinical stage and develop resistance to standard of care platinum/taxane therapy. Doxorubicin is also approved for ovarian cancer but had limited benefits in refractory patients. In this study, we used drug-resistant spheroid cultures of ovarian carcinoma to evaluate the uptake and cytotoxicity of an antibody-targeted doxorubicin formulation. Doxorubicin was encapsulated in polyethylene glycol-phosphatidyl ethanolamine (PEG-PE) conjugated micelles. The doxorubicin-loaded PEG-PE micelles (MDOX) were further decorated with a cancer cell-specific monoclonal 2C5 antibody to obtain doxorubicin-loaded immunomicelles (2C5-MDOX). Targeting and resulting toxicity of doxorubicin-loaded PEG-PE micelles were evaluated in three dimensional cancer cell spheroids. Superior accumulation of 2C5-MDOX compared to free doxorubicin or untargeted MDOX in spheroids was evidenced both by flow cytometry, fluorescence and confocal microscopy. Interestingly, even higher toxicity was measured by lactate dehydrogenase release and terminal deoxynucleotidyl transferase dUTP nick end labeling of targeted doxorubicin micelles in Bcl-2 overexpressing adriamycin-resistant spheroids. Overall, these results support use of spheroids to evaluate tumor targeted drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.